FY2026 Earnings Estimate for Alnylam Pharmaceuticals, Inc. Issued By Zacks Research (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities research analysts at Zacks Research lifted their FY2026 EPS estimates for shares of Alnylam Pharmaceuticals in a report issued on Tuesday, September 24th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of $2.15 for the year, up from their prior forecast of $2.11. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.73) per share.

Several other brokerages have also weighed in on ALNY. Cantor Fitzgerald reissued a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, September 9th. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. Citigroup upped their target price on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, August 30th. Finally, UBS Group boosted their price target on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a research note on Friday, June 28th. Seven analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $279.14.

Alnylam Pharmaceuticals Trading Up 0.1 %

ALNY opened at $274.91 on Friday. The stock’s fifty day simple moving average is $263.00 and its 200 day simple moving average is $203.41. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $287.55. The stock has a market cap of $34.77 billion, a PE ratio of -102.58 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The company’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($2.21) EPS.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC boosted its holdings in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $26,000. Altitude Crest Partners Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $30,000. V Square Quantitative Management LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $52,000. Finally, Prestige Wealth Management Group LLC lifted its holdings in Alnylam Pharmaceuticals by 69.8% in the first quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 194 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,829,070. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,148 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $19,829,070. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at approximately $35,632. The disclosure for this sale can be found here. Insiders sold a total of 57,491 shares of company stock valued at $15,446,733 in the last quarter. Insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.